Anti-PD-L1 antibodies
US10981995B2 · kind B2 · utility
1Cited by
13References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 5, 2016 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Oct 7, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-L1 on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.